Priority 10 from the Myeloma (Canada) PSP
|UNCERTAINTY: Can we develop treatments specifically for high risk or aggressive myeloma that will improve outcomes for these patients? (JLA PSP Priority 10)
|JLA question ID
|High risk or aggressive myeloma is defined by disease stage, chromosomal abnormalities, disease biology, and gene expression, and is associated with worse outcomes. Participants want to know about the current treatment options and the new treatments for patients with high risk or aggressive myeloma (including those with genetic abnormalities, deletions, etc.) that will improve outcomes for these patients?
No evidence identified
|Health Research Classification System category
|Cancer and neoplasms
|Extra information provided by this PSP
|Original uncertainty examples
|Are there individual drugs that can be isolated to the treatment of specific myeloma conditions such as high risk factors? ~ How can outcomes be better for those with high risk myeloma (genetic abnormalities, deletions, etc) ~ More research for specific treatments for high risk myeloma Results of larger studies broken down to show results for high risk patients separately from regular myeloma patients ~ What treatments are most effective for those living with a P53 diagnosis.
|Please see the PSP Engagement Summary on the JLA website
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|28 April 2021